The Food and Drug Administration has signaled in recent interagency communications and Congressional testimony that it is targeting 2027 as the timeframe for completing a formal rulemaking on the status of CBD and other hemp-derived cannabinoids as food ingredients and dietary supplement components. While the agency has not published a final rule or official rulemaking schedule, the signals are consistent enough to warrant attention from B2B hemp ingredient suppliers whose customers operate in the food, beverage, and dietary supplement sectors.
Background: The Regulatory Limbo That Has Defined CBD Since 2018
Since the passage of the 2018 Farm Bill legalized hemp cultivation, CBD has occupied an anomalous regulatory position. The FDA determined in 2019 that because CBD was first approved as a drug ingredient in Epidiolex, it was excluded from the food additive and dietary supplement regulatory pathways under existing statutory authority (sections 201(ff)(3)(B) and 331(ll) of the Food, Drug, and Cosmetic Act).
This determination effectively blocked the legal marketing of CBD as a food ingredient or dietary supplement at the federal level — even as an enormous gray market for CBD products emerged and state-level regulations varied widely. The hemp industry has operated in this gap ever since.
Multiple FDA Commissioners and senior agency officials have acknowledged the limitations of the current framework and called on Congress to provide a legislative pathway. In the absence of that pathway, the FDA is now signaling it may use its existing regulatory authority to establish a framework, rather than waiting indefinitely for Congress to act.
What the 2027 Signal Means
A 2027 rulemaking target, if it holds, would mean that hemp-derived CBD and potentially other phytocannabinoids could receive explicit regulatory status as lawful food or supplement ingredients within approximately 18 months. For B2B hemp ingredient suppliers and their customers, this would represent the most significant regulatory development since the 2018 Farm Bill.
A few important caveats apply:
Rulemaking timelines slip. The FDA's rulemaking schedule is not a public commitment. The agency has signaled intent, not a deadline. The 2027 target could shift depending on agency resources, administration priorities, litigation, or Congressional action.
Rulemaking establishes conditions, not blanket approval. A final rule on CBD as a food or supplement ingredient would likely establish maximum use levels, required disclosures, prohibited claims, and manufacturing standards. It would not be a green light for unconstrained marketing.
The Hemp Safety Enforcement Act framework is separate. The THC limits, testing requirements, and documentation standards under HSEA govern all hemp products regardless of how the FDA resolves the CBD rulemaking question. These are two parallel regulatory tracks.
Implications for B2B Ingredient Buyers
For manufacturers formulating with hemp-derived CBD in food and supplement applications, a 2027 rulemaking would have several practical consequences:
Label claims may shift. Once CBD is formally authorized as a food or supplement ingredient, the FTC and FDA frameworks for substantiated health claims will apply more explicitly. This may open claim opportunities that were previously unavailable, but it will also expose brands making unsubstantiated claims to greater regulatory scrutiny.
Retailer gatekeeping may relax. Several major national retailers have declined to expand hemp-derived CBD product categories precisely because of the federal regulatory ambiguity. A formal FDA authorization could unblock retail channel expansion for brands that have been waiting for regulatory clarity.
Documentation requirements may increase. A formal rule will almost certainly require more rigorous documentation of CBD content, sourcing, and manufacturing practices than the current gray market standard. Brands that have already built compliant supply chains under the HSEA framework will be well-positioned; those relying on informal sourcing relationships may face a steep compliance ramp.
Ingredient specifications may need updating. If the FDA establishes maximum CBD use levels or requires specific forms of documentation for food-grade CBD, ingredient specification sheets and COAs may need to be updated to reflect new regulatory categories.
What Suppliers Should Be Doing Now
For hemp ingredient suppliers whose customers are in food, beverage, and supplement manufacturing, the 2027 rulemaking signal is a reason to begin preparing now:
- Review current ingredient documentation and identify gaps relative to likely FDA documentation requirements for food-grade ingredients
- Engage with food industry legal counsel to understand how a formal CBD authorization would interact with existing label claims and formulation disclosures
- Monitor FDA's regulatory agenda and the Congressional debate over CBD to track any changes in the rulemaking timeline
- Begin conversations with B2B customers about how a formal authorization would affect their product roadmaps and ingredient sourcing plans
The Competitive Landscape After Rulemaking
A formal FDA authorization of CBD as a food or supplement ingredient would almost certainly accelerate market entry by large conventional food and beverage manufacturers who have been monitoring the category but deferring investment. For the hemp ingredient supply chain, this means a potential surge in ingredient demand — and significantly heightened scrutiny of supplier quality systems and documentation.
Suppliers who are compliant under the HSEA framework today will have a head start. Those who have not built GMP-certified manufacturing, DEA-registered lab testing relationships, and robust documentation packages will be scrambling to catch up at the same moment that demand is increasing.
Conclusion
The FDA's 2027 rulemaking signal is not a guarantee — but it is a credible indicator that the regulatory limbo surrounding CBD as a food and supplement ingredient is approaching resolution. For B2B hemp ingredient suppliers and their customers, the window between now and a potential 2027 rule is the time to build the supply chain infrastructure and documentation practices that will be required when that rule arrives.
Low Gravity Hemp supplies B2B hemp ingredients with documentation packages built for regulated food, beverage, and supplement manufacturing. Contact us to discuss how our current documentation stack aligns with anticipated FDA requirements.
